Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada

Rheumatology

Volumn 45, Issue 7, 2006, Pages 903-910

  Rahme, Elham ^a   Toubouti, Y ^a   Hunsche, E ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cost analysis; Cyclooxygenase 2 inhibitors; Non steroidal anti inflammatory agents; Prescriptions

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARTHROTEC; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

AGED; ARTICLE; CANADA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG COST; DRUG EXPOSURE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HAZARD ASSESSMENT; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; LACTONES; MALE; MUSCULOSKELETAL DISEASES; PRESCRIPTIONS, DRUG; PYRAZOLES; QUEBEC; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES;

EID: 33745620466     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei269     Document Type: Article

References (39)

1. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
2. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995;40:1345-50.
3. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104: 23S-29S.
4. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
5. Lisse JR, Perlman M, Johansson G et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: A randomized, controlled trial. Ann Intern Med 2003;139:539-46.
6. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
7. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthriAis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247-55.
8. Laine L, Connors LG, Reicin A et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92.
9. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. Br Med J 2002;325: 619.
10. Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Br Med J 2002;324:1287-8.
11. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6.
12. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
13. Hampton T. Officials halt NSAID prevention trials. J Am Med Assoc 2005;293:664-5.
14. Health Canada. Report of the Expert Advisory Panel on the safety of Cox-2 selective non-steroidal anti-inflammatory drugs (NSAIDs). Health Canada website (accessed 19 August 2005). (http://www.hc-sc.gc.ca/ dhp-mps/prodpharma/activit/sci-consult/cox2/ sap_report_gcs_rapport_cox2_e.html).
15. Jenkins JJ, Seligman PJ (US Food and Drug Administration). Memorandum: analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Center for Drug Evaluation and Research website (accessed 19 August 2005). (http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf).
16. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults. Ann Intern Med 2005;142:481-9.
17. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
18. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.
19. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003;63:525-34.
20. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 2002;359:118-23.
21. Langman M, Kahler KH, Kong SX et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: A retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001;10: 517-24.
22. Sift R, van Staa TP, Abenhaim L, Ebner D. A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf 1997;6:263-8.
23. Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-95.
24. Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol 2004;31:355-8.
25. Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004;13:277-87.
26. Harley C, Wagner S. Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Manag Care Interface 2003;16:38-45.
27. Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology 2003; 42(Suppl 3): Iii17-iii22.
28. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-24.
29. World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva, World Health Organization, 2003.
30. ICD9.CM millennium edition: International Classification of Diseases, ninth revision, clinical modification, 6th edn. Los Angeles: Practice Management Information Corporation (PMIC), 2003.
31. Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.
32. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review. Br Med J 2004;329:948-57.
33. Federal Reserve Statistical Release. G.5 A: Foreign exchange rates (annual). US Federal Reserve Board website (accessed 11 March 2005) (http://www.federalreserve.gov/releases/g5a/20030106/).
34. Bennett K, Teeling M, Feely J. 'Selective' switching from non-selective to selective non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2003;59:645-9.
35. Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: A population-based case-control study. Arthritis Res Ther 2005;7: R333-R342.
36. Schnitzer TJ, Kong SX, Mitchell JH et al. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther 2003;25:3162-72.
37. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
38. Savitz A. Interpreting epidemiologic evidence: Strategies for study design and analysis. New York, NY: Oxford University Press, 2003.
39. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004;57:131-41.